Prohost Letter #412 Part 1
Updating Our Targets - This Letter will be of three parts. The first part (today’s issue)aims at presenting our adjusted targets based on current news and updates related to the Prohost picks.
A Case in Point - PORTOLA - For example, Portola (PTLA) has recently been granted FDA approval for its Factor 10 (FX) inhibitor anticoagulant drug Bevyxxa (betrixaban . . .
This content is for paid subscribers.
Prohost Letters July 24, 2017